ALLISON TRACHUK
** ******** ***** *******, ** ***91 C: 925-***-**** ********@*****.***
PROFESSIONAL SUMMARY
Associate Scientist with over 15 years of industry experience working in both discovery and GLP compliant environments. Main background in biocharacterization and assay development. EDUCATION
Bachelor of Science in Biological Sciences, Molecular and Cellular Biology University of California, Davis (2010)
SKILLS
Extensive knowledge of passaging and maintaining mammalian cell lines, creating cell banks, stable pool generation, and troubleshooting growth issues..
Proficient in a variety of Biocharacterization techniques including Western blot, ELISA, flow cytometry, cytotoxicity assays, and Octet.
Trained in working with non-clinical and clinical samples such as serum, plasma, whole blood, PBMC’s, and urine.
Experience using MSD readers ELLA, Softmax, Luminex, BDFACS, Cytek Northern Lights, and ELIspot platforms.
EXPERIENCE
Associate Scientist, Catalent Pharma (June 2023-Present)
Responsible for a large variety of primarily mammalian cell lines through passaging, optimizing conditions, and maintaining an accurate and up to date inventory at all times. Responsibilities include creating cell banks, stable pool generation, troubleshooting growth condition.
Tests antibody and ADC binding and internalization characteristics through ELISA, Octet, Incucyte, or flow cytometry-based methods
Performs and develops in vitro cytotoxicity studies to test the potency of ADCs and cytotoxic payloads.
Develops new and/or optimize existing analytical assays
Functions as a key contributing member of the Biocharacterization team, proactively communicating results and contributing to troubleshooting
Shares results and ideas across the site’s multidisciplinary teams
Generates data to support strategic partner relationships, platform development, patents, publications, and wrote IND reports
Senior Research Associate, Nektar Therapeutics (October 2019-June 2023)
Provides Analytical Support for process characterization of Nektar's biological drugs
Determines methods and procedures on new assignments and acts as principal investigator in conducting own experiments
Provides and presents scientific data to process scientists
Performs HCP ELISA, BCA protein assay, DNA quantification, and UV/VIS spectrometry, SDS-page analysis.
Maintains a variety of cell lines/banks for use in BioAssay Development. Responsible for performing testing with these cell lines and delivering timely results. Research Associate II, Fluidigm (February 2019-October 2019)
Performed a variety of antibody-metal tag conjugations for use in multiplex assays.
Performed tissue culture for cell lines related to the validation and QC of the tagged antibodies which will be offered in the catalog.
Performed quality control testing using standard ICP-Mass Spectrometry as well as Mass Cytometry technology on the CyTOF instruments.
Senior Research Associate, Aduro Biotech (August 2018-February 2019)
Worked with team on assay development and optimization, performed routine immune assays using human biological samples, and performs following data analysis.
Drafts summary reports, protocols, and other documentation.
Represented team and present data at cross-functional project teams. Research Associate II, BioMarin Pharmaceuticals (November 2014-August 2018)
Performed quantitative and semi-quantitative assays on samples including immunoassays for therapeutic protein concentration and antibodies to therapeutic proteins and enzymatic activity.
Prepared data reports, deviation reports, change requests, assay SOPs. Revise and review process SOPs and departmental forms, prepare validation reports.
Characterized and validated cell based NAb assay on the spectramax platform and developed a PK assay to be used with the MSD reader. Biorepository Scientist, Roche Molecular Diagnostics (October 2010-November 2014)
Received and processed biological specimens across all RMD Life Cycle Teams.
Maintained optimum quality of samples and resolved discrepancies.
Coordinated equipment calibration/validation, acquisition, return, and decommission.